| COMPANY |
BioAge Labs, Inc. |
| COURT |
United States District Court for the Northern District of California |
| CASE NUMBER |
3:25-cv-00196 |
| JUDGE |
The Hon. Richard G. Seeborg |
| CLASS PERIOD |
Pursuant and/or traceable to IPO on or about September 26, 2024 |
| SECURITY TYPE |
Stock |
Case Background:
The Class Period begins on September 26, 2024, when BioAge filed its final prospectus for the company’s IPO, which was incorporated into the registration statement, and listed for sale 11 million shares of BioAge common stock at an offering price of $18 per share. BioAge’s final prospectus for the IPO represented the significance and benefits of azelaprag for the treatment of obesity in older adults. Specifically, BioAge touted azelaprag in connection with the company’s ongoing STRIDES Phase 2 trial and represented that there were no safety concerns and that BioAge expected top line results to meet its primary endpoint goals in connection with its STRIDES clinical trial.
The complaint alleges that, in the registration statement and prospectus issued in connection with BioAge’s IPO, Defendants made false and/or misleading statements and/or failed to disclose information pertinent to investors concerning BioAge’s STRIDES Phase 2 trial for azelaprag. Specifically, Defendants misrepresented and/or failed to disclose: (1) the potential for liver transaminitis in any of its previous clinical STRIDES Phase 1 trials and various preclinical tox studies; (2) that there were no safety concerns and that BioAge expected top line results and to meet its primary endpoint goals in connection with its STRIDES clinical trial; and (3) as a result, Defendants’ statements about the company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Current Status of Case:
Defendants filed the Motion to Dismiss the First Amended Complaint on July 9, 2025. This action is ongoing.
If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.